The Technical Analyst

CoreSite Realty Corp [COR]

Exchange: NYSE Sector: Real Estate Industry: REIT—Specialty

CoreSite Realty Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals

-1.16% $224.11

America/New_York / 8 mai 2024 @ 16:00

FIND ALL MARKETS FIND ALL STOCKS LISTED @ NYSE Live Signal Oslo Live Signal Nasdaq Live Signal Crypto

CoreSite Realty Corp: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap:	44 699 mill
EPS:	9.14
P/E:	24.52
Earnings Date:	Jul 31, 2024
SharesOutstanding:	199.45 mill
Avg Daily Volume:	1.241 mill

RATING 2024-05-08
S-
Strong Buy

RATINGS
Rating CashFlow:	Strong Buy
Return On Equity:	Strong Buy
Return On Asset:	Neutral
DE:	Strong Buy
P/E:	Buy
Price To Book:	Strong Buy

QUARTER GROWTHS
	4/22	1/23	2/23	3/23	4/23	1/24
Revenue
Gr.Profit
Ebit
Asset
Debt

PE RATIO: COMPANY / SECTOR
0.80x
Company: PE 24.52 \| sector: PE 30.55

PE RATIO: COMPANY / INDUSTRY
1.05x
Company: PE 24.52 \| industry: PE 23.40

DISCOUNTED CASH FLOW VALUE
$565.61 (152.38%) $341.50
Date: 2024-05-09

Expected Trading Range (DAY)
$ 220.77 - 227.45 ( +/- 1.49%)
ATR Model: 14 days

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Tyler Lauren M	Buy	110	Common Stock
2024-05-01	Baumann Werner	Buy	110	Common Stock
2024-05-01	Nally Dennis M	Buy	137	Common Stock
2024-04-15	Mauch Robert P.	Buy	33 877	Common Stock
2024-04-15	Mauch Robert P.	Sell	57 564	Common Stock

INSIDER POWER
-94.97
Last 100 transactions
Buy: 2 602 570 \| Sell: 9 506 424

Forecast: 16:00 - $224.08

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $224.08

Forecast 2: 16:00 - $224.08

Forecast 3: 16:00 - $224.08

SCORE
10.00
Buy

Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022

Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD

Volume Signals
Price	$224.11 (-1.16% )
Volume	1.544 mill
Avg. Vol.	1.241 mill
% of Avg. Vol	124.39 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for CoreSite Realty Corp

Last 12 Months

RSI

Intraday RSI14 chart for CoreSite Realty Corp

Last 10 Buy & Sell Signals For COR

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date	Signal	@	Closed	%

COR

Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Last 10 Buy Signals

Date	Signal	@
FTSEMIB.MI	May 9 - 08:01	34 084
ZSUSX	May 9 - 08:04	1 228.25
ZLUSX	May 9 - 08:04	43.66
ASRUSD	May 9 - 08:11	3.17
NULSUSD	May 9 - 08:10	$0.641
GHSTUSD	May 9 - 08:08	$1.723
GRSUSD	May 9 - 08:08	$0.529
DCRUSD	May 9 - 08:05	$19.37
ARKUSD	May 9 - 08:05	$0.791
HAPIUSD	May 9 - 08:05	18.70

Latest Press Releases

2024-05-08 08:30:00 - Press Release

Cencora To Host Inaugural Thinklive Cell And Gene Therapy Summit

Conshohocken, pa.--(business wire)--cencora, a global healthcare company, will convene leaders from across the healthcare and biopharmaceutical industries for its inaugural thinklive cell and gene therapy (cgt) summit, an event designed to explore the latest developments in the cgt sector and strategies to accelerate product commercialization and patient access. the two-day virtual event, which kicks off may 14, will feature panel discussions and presentations that cover key topics and consider.

2024-05-01 06:30:00 - Press Release

Cencora Reports Fiscal 2024 Second Quarter Results

Conshohocken, pa.--(business wire)--cencora, inc. (nyse: cor) today reported that in its fiscal year 2024 second quarter ended march 31, 2024, revenue increased 7.8 percent year-over-year to $68.4 billion. on the basis of u.s. generally accepted accounting principles (gaap), diluted earnings per share (eps) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in the prior year second quarter. adjusted diluted eps, which is a non-gaap financial measure that excludes items described.

2024-04-05 08:30:00 - Press Release

Cencora Announces Date And Time For Second Quarter Fiscal 2024 Earnings Release

Conshohocken, pa.--(business wire)--cencora, inc. (nyse: cor) today announced that it plans to release its results for the second quarter of fiscal 2024 on wednesday, may 1, 2024, prior to the opening of trading on the new york stock exchange. the company will host a conference call to discuss the results at 8:30 a.m. et on may 1, 2024. participating in the conference call will be: steven h. collis, chairman, president & chief executive officer james f. cleary, executive vice president &.

2024-03-12 08:30:00 - Press Release

Cencora Announces Leadership Succession Plan

Conshohocken, pa.--(business wire)--cencora, inc. (nyse: cor) today announced that steven h. collis will retire as president and chief executive officer of the company and transition to the role of executive chair of the cencora board of directors, effective october 1, 2024. robert p. mauch, pharmd, phd, current chief operating officer of cencora, will succeed collis as president and ceo, and will also be appointed as a member of the company's board, effective the same date. “steve's 30-year ca.

2024-02-07 18:26:00 - Press Release

Cencora Announces Common Share Repurchase From Walgreens Boots Alliance

Conshohocken, pa.--(business wire)--cencora, inc. (nyse: cor) today announced that it has agreed to repurchase shares of its common stock from walgreens boots alliance holdings llc in the amount of approximately $50 million in concurrence with walgreens boots alliance's sale of cencora shares pursuant to rule 144 under the securities act of 1933, as amended. cencora intends to repurchase shares from walgreens boots alliance at the price per share equal to the price in the rule 144 sale. the con.

Latest News

2024-05-01 23:01:08 - Zacks Investment Research

Cencora (COR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Cencora (COR) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Full Story

2024-05-01 09:46:13 - Zacks Investment Research

Cencora (COR) Q2 Earnings Top Estimates, 2024 View Raised

Cencora's (COR) second-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Full Story

2024-05-01 08:41:08 - Zacks Investment Research

Cencora (COR) Q2 Earnings Top Estimates

Cencora (COR) came out with quarterly earnings of $3.80 per share, beating the Zacks Consensus Estimate of $3.65 per share. This compares to earnings of $3.50 per share a year ago.

Full Story

2024-05-01 07:43:27 - Reuters

Cencora beats profit estimates on strong demand for costly specialty drugs

Cencora beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for costly specialty medicines that treat complex diseases such as cancer and rheumatoid arthritis.

Full Story

2024-04-26 10:21:07 - Zacks Investment Research

Cencora (COR) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Beyond analysts' top -and-bottom-line estimates for Cencora (COR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Full Story

2024-04-23 06:24:00 - InvestorPlace

3 High-Quality Stocks That Will Never Put You in the Red

Every portfolio needs a solid foundation of high-quality stocks that can provide steady returns through all market environments. While I often discuss more speculative growth and penny stock plays in my articles that some view as high-risk, high-reward bets, the core of your portfolio should revolve around a select few tried-and-true companies.

Full Story

2024-04-15 10:46:41 - Zacks Investment Research

Here's Why Cencora (COR) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Full Story

2024-04-12 10:50:37 - Zacks Investment Research

Here's Why Cencora (COR) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Full Story

2024-04-05 08:30:00 - Business Wire

Cencora Announces Date and Time for Second Quarter Fiscal 2024 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2024 on Wednesday, May 1, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 1, 2024. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President &.

Full Story

2024-04-04 10:16:10 - Zacks Investment Research

Cencora, Inc. (COR) Soars to 52-Week High, Time to Cash Out?

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Full Story

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.